الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
Morbid obesity is now an important problem all over the world due to its multiple co-morbidities and its marked harmful effect on the lifestyle of the patients. When dietary and behavioural approaches to obesity meet limited success, bariatric surgery is the only effective therapy for morbid obesity.
LSG has emerged as an effective stand-alone procedure in the thriving world of bariatric surgery. The literature has moved away from labeling it as a purely restrictive procedure, as its interactions with gut hormones (e.g. ghrelin and PYY) are now well-recognized.
Benefits of LSG include not only durable long lasting treatment for morbid obesity but also abolishing many of its related co-morbid conditions, including type II diabetes mellitus, metabolic syndrome, osteoarthritis of weight bearing joints, obstructive sleep apnea and hyperlipidaemia. As more long-term data becomes available, the true value of this bariatric procedure will be fully recognized.
Our study showed that LSG is effective in achieving weight loss, at 6 weeks it ranged from 12.5% to 40.1% (mean ± SD= 29.75 ± 7.55). At 3 months, EWL% for all cases ranged from 22.6% to 70% (mean ± SD= 51.76 ± 9.81). At 6 months, EWL% for all cases ranged from 27.4% to 88.5% (mean ± SD= 70.54 ± 12.53). After one year EWL % for all cases had a minimum of 28.6% and a maximum of 97.3% (mean ± SD= 83.29 ± 14.91).
Our results proved symptomatic resolution of obesity-related co-morbidities regarding symptoms of knee pain related to weight-related osteoarthritis.
Improvement of the metabolic profile of patients was evident after surgery, namely the blood sugar level and lipid profile. Postoperative FBS levels improved – in comparison to the preoperative levels - with significant decrease particularly at 3, 6 and 12 months after surgery. Postoperative 2-hours postprandial blood sugar levels also improved – in comparison to preoperative levels - with significant decrease particularly at 6 and 12 months. At the end of study, remission of type II diabetes was seen in all the diabetic patients (5 cases, 10%) in our study.
Before surgery, 20 patients have asymptomatic hypertriglyceridaemia and/or hyercholesterolaemia. Significant reduction in the levels of serum triglycerides and total cholesterol began as early as 4 weeks after surgery and continued throughout the period of follow up.